Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chromadex Corp CS
(NQ:
CDXC
)
3.340
+0.040 (+1.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Chromadex Corp CS
< Previous
1
2
3
4
5
6
Next >
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
January 26, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
December 20, 2023
From
ChromaDex Corporation
Via
Business Wire
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
November 30, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
November 15, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
November 09, 2023
From
ChromaDex Corporation
Via
Business Wire
Earnings Outlook For ChromaDex
November 07, 2023
Via
Benzinga
Recap: ChromaDex Q1 Earnings
May 10, 2023
Via
Benzinga
ChromaDex Earnings Perspective: Return On Capital Employed
March 10, 2023
Via
Benzinga
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
November 08, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
November 01, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
October 31, 2023
From
ChromaDex Corporation
Via
Business Wire
Earnings Preview: ChromaDex
March 07, 2023
Via
Benzinga
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
October 26, 2023
From
ChromaDex Corporation
Via
Business Wire
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
August 24, 2023
From
ChromaDex Corporation
Via
Business Wire
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
October 02, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
August 09, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
August 08, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
August 07, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
August 02, 2023
From
ChromaDex Corporation
Via
Business Wire
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
July 18, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging
June 16, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in the LD Micro Invitational XIII
May 30, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
May 11, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports First Quarter 2023 Financial Results
May 10, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
May 02, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
March 08, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023
March 06, 2023
From
ChromaDex Corpor
Via
Business Wire
Earnings Scheduled For March 8, 2023
March 08, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
Via
Benzinga
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
February 27, 2023
From
ChromaDex Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.